Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Syndax Pharmaceuticals Inc

Get SEC filing alerts via email and in your feed for Syndax Pharmaceuticals Inc

SNDX

Syndax Pharmaceuticals Inc

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is a biopharmaceutical company focused on developing innovative cancer therapies. Its core products include FDA-approved revumenib for acute leukemia and axatilimab for chronic graft-versus-host disease, with ongoing clinical programs in oncology and fibrotic diseases. The company leverages licensing, collaborations, and a strong pipeline to address unmet medical needs in hematology, oncology, and fibrosis markets worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Syndax Pharmaceuticals Inc

1
1
Syndax Pharmaceuticals Inc Syndax Pharmaceuticals Reports $64.9 Million in Quarterly Revenues, Driven by Revuforj Sales

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Syndax Pharmaceuticals Inc Syndax Pharmaceuticals Reports $172.4 Million Revenue with Significant Growth from Revuforj

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Syndax Pharmaceuticals Inc Syndax Pharmaceuticals Reports $45.9M Revenue in Q3 2025, Net Loss Improves

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Syndax Pharmaceuticals Inc Syndax Pharmaceuticals Reports $37.96 Million Revenue for Q2 2025, Net Loss of $71.85 Million

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Syndax Pharmaceuticals Inc Syndax Pharmaceuticals Reports $84.8 Million Net Loss in Q1 2025, Highlights Revenue from Revuforj

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Syndax Pharmaceuticals Inc Syndax Pharmaceuticals Reports $318.8 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Syndax Pharmaceuticals Inc Syndax Pharmaceuticals Reports Significant Revenue Growth, Increased Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments